Medical isotope developer IsoRay Medical has announced a distribution agreement with Oncura, a GE Healthcare subsidiary, to distribute its OncoSeed I-125 brachytherapy seed.
Richland, WA-based IsoRay expects that the ability to offer I-125 seeds will allow it to expand cesium-131 sales through group purchasing organization contracts that require multiple sources from a single provider.
Further, IsoRay anticipates strategic value in supporting customers who have not yet converted their practice to cesium-131 for the treatment of a variety of anatomic sites including prostate.
Related Reading
IsoRay adds Canadian distributor, November 18, 2009
IsoRay touts cesium-131 treatment, September 28, 2009
IsoRay's 2009 results dip, September 24, 2009
IsoRay nets FDA OK on seeds, August 18, 2009
IsoRay sales drop, loss narrows, May 18, 2009
Copyright © 2009 AuntMinnie.com
